摘要
目的:研究高剂量瑞舒伐他汀对PCI术后患者血小板功能影响,进一步探讨他汀类药物与血小板功能的关系。方法:92例择期行PCI术的冠心病患者分为瑞舒伐他汀5mg组(R5组,n=30)、瑞舒伐他汀20mg组(R20组,n=31)、阿托伐他汀20mg组(A20组,n=31),同期行冠脉造影的非冠心病患者30例作为单纯冠状动脉造影组(单纯CAG组)。通过流式细胞检测术,比较术前及术后24h四组血小板活化标志物CD62P、CD63变化。结果:R5、R20和A20组CD62P百分率术后较术前均有不同程度的升高(P<0.05),单纯CAG组术后无明显升高(P>0.05)。与R20组相比,R5、A20组术后CD62P百分率显著升高,差异均有统计学意义(P<0.05);术后R5组CD62P百分率与A20组比较,差异无统计学意义(P>0.05)。术后,R5、A20组CD63百分率明显高于R20组,差异均有统计学意义(P<0.05)。R5组CD63百分率与A20组比较,差异无统计学意义(P>0.05);R20组CD63百分率与单纯CAG组比较,差异无统计学意义(P>0.05)。结论:血小板活化标志物检测表明经皮冠脉介入术术后循环外周血小板活性增高,对评估术后患者血小板功能状态具有积极意义;瑞舒伐他汀具有抑制血小板作用,并随剂量升高而加强,并且安全有效,PCI术前负荷剂量服用可使患者获益更多。
Objective： To assess the influence of high dose Rosuvastatin on platelet function in patients after PCI.Method： A total of 92 coronary heart disease （ CHD ） patients underwent PCI were divided into Rosuvastatin 5 mg group （ R5 group, n=30 ）, Rosuvastatin 20 mg group （ R20 group, n=31 ） and Atorvastatin 20 mg （ A20 group, n=31 ）, 30 non-CHD patients were recruited as the coronary arteriongraphy group （ CAG group ） . Platelet activation markers CD62P and CD63 of four groups were examined by flow cytometry before operation and 24 hours after operation.Result; The percentage of CD62P in R5 group, R20 group and A20 group were significantly increased after operation （ P〈0.05 ）, but the percentage of CD62P in CAG group was non-significantly increased （ P〉0.05 ） .Compared with the R20 group, the percentage of CD62P in R5 group and A20 group were significantly higher, the differences had statistical significance （ P〈O.05 ） ; there were no statistical significance in the percentage of CD62P in R5 group and R20 group after operation （ P〉0.05 ） .After operation, the percentage of CD63 in R5 group and A20 group were significantly higher than R20 group, the differences had statistical significance （P〈0.05 ） .There was no difference in the percentage in CD63 of R5 group and A20 group （ P〉0.05 ） ; and there was no difference in the percentage of CD63 in R20 group and CAG group （ P〉0.05 ） .Conclusion： The results of platelet activation markers indicate that peripheral platelet is remarkable activated after PCI, which may be a effective method to evaluate platelet function after PCI; Rosuvastatin has an effect to inhibit platelet function, and it＇s dose related, which indicated patients can be benefited from loading doses of Rosuvastatin before PCI.
出处
《中国医学创新》
CAS
2017年第25期1-5,共5页
Medical Innovation of China
基金
广东省江门市科技局科技项目(2016年98号第28项)
